BioCryst Pharma (BCRX) Misses Q4 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $7.65 -1.67%
EPS Growth %: -43.8%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -43.8%
Financial Fact:
Basic and diluted net loss per common share: -0.16
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
(Updated - February 26, 2024 7:57 AM EST)
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.4 million versus the consensus estimate of $89.97 million.
GUIDANCE:
BioCryst Pharma sees FY2024 ORLADEYO revenue of $380-400 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Accenture shares fall on insider sales and analyst downgrade
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
